Population pharmacokinetic models of tacrolimus in paediatric solid organ transplant recipients: A systematic review
- 4 October 2023
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 90 (2) , 406-426
Abstract
Aims: This study aimed to provide up‐to‐date information on paediatric population pharmacokinetic models of tacrolimus and to identify factors influencing tacrolimus pharmacokinetic variability.Methods: Systematic searches in the Web of Science, PubMed, Scopus, Science Direct, Cochrane, EMBASE databases and reference lists of articles were conducted from inception to March 2023. All population pharmacokinetic studies of tacrolimus using nonlinear mixed‐effect modelling in paediatric solid organ transplant patients were included.Results: Of the 21 studies reviewed, 62% developed from liver transplant recipients and 33% from kidney transplant recipients. Most studies used a 1‐compartment model to describe tacrolimus pharmacokinetics. Body weight was a significant predictor for tacrolimus volume of distribution (Vd/F). The estimated Vd/F for 1‐compartment models ranged from 20 to 1890 L, whereas the peripheral volume of distribution (Vp/F) for 2‐compartment models was between 290 and 1520 L. Body weight, days post‐transplant, CYP3A5 genotype or haematocrit were frequently reported as significant predictors of tacrolimus clearance. The estimated apparent clearance values range between 0.12 and 2.18 L/h/kg, with inter‐individual variability from 13.5 to 110.0%. Only 29% of the studies assessed the generalizability of the models with external validation.Conclusion: This review highlights the potential factors, modelling approaches and validation methods that impact tacrolimus pharmacokinetics in a paediatric population. The clinician could predict tacrolimus clearance based on body weight, CYP3A5 genotype, days post‐transplant or haematocrit. Further research is required to determine the relationship between pharmacogenetics and tacrolimus pharmacodynamics in paediatric patients and confirm the applicability of nonlinear kinetics in this population.Keywords
This publication has 40 references indexed in Scilit:
- Effects of Combinational CYP3A5 6986A>G Polymorphism in Graft Liver and Native Intestine on the Pharmacokinetics of Tacrolimus in Liver Transplant PatientsTherapeutic Drug Monitoring, 2014
- Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipientsBritish Journal of Clinical Pharmacology, 2014
- Population Pharmacokinetic Analysis of Tacrolimus Early After Pediatric Liver TransplantationTherapeutic Drug Monitoring, 2014
- CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patientsPediatric Transplantation, 2014
- Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patientsBritish Journal of Clinical Pharmacology, 2013
- Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipientsPharmacogenetics and Genomics, 2013
- Fundamentals of Population Pharmacokinetic ModellingClinical Pharmacokinetics, 2012
- Population Pharmacokinetics of Tacrolimus in Pediatric Liver Transplantation: Early Posttransplantation ClearanceTherapeutic Drug Monitoring, 2011
- Factors Affecting the Apparent Clearance of Tacrolimus in Korean Adult Liver Transplant RecipientsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Clinical pharmacogenetics of immunosuppressive drugs in organ transplantationPharmacogenomics, 2005